Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 3:02 pm Purchase | 2021-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | Cormorant Asset Management LP | 3,025,000 6.110% | 632,703 (+26.45%) | Filing History |
| 2022-02-14 2:35 pm Purchase | 2021-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | PRICE T ROWE ASSOCIATES INC | 3,811,568 7.700% | 1,265,783 (+49.72%) | Filing History |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | VANGUARD GROUP INC | 3,877,339 7.840% | 436,879 (+12.70%) | Filing History |
| 2022-02-09 10:01 am Sale | 2022-02-08 | 13G | Turning Point Therapeutics, Inc. TPTX | FMR CORP | 1,398,602 2.826% | -1,775,067 (-55.93%) | Filing History |
| 2022-02-04 09:24 am Purchase | 2021-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | WELLINGTON MANAGEMENT CO LLP | 4,009,654 8.100% | 4,009,654 (New Position) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | BlackRock Inc. BLK | 3,783,325 7.600% | 625,938 (+19.82%) | Filing History |
| 2021-06-10 11:37 am Sale | 2021-06-09 | 13G | Turning Point Therapeutics, Inc. TPTX | FMR CORP | 3,173,669 6.456% | -3,041,693 (-48.94%) | Filing History |
| 2021-04-07 4:39 pm Sale | 2021-03-01 | 13D | Turning Point Therapeutics, Inc. TPTX | ORBIMED ADVISORS LLC | 1,743,950 3.600% | -283,600 (-13.99%) | Filing History |
| 2021-02-16 3:12 pm Sale | 2020-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | Cormorant Asset Management LP | 2,392,297 4.960% | -1,004,353 (-29.57%) | Filing History |
| 2021-02-16 12:24 pm Purchase | 2020-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | PRICE T ROWE ASSOCIATES INC | 2,545,785 5.200% | 2,545,785 (New Position) | Filing History |
| 2021-02-10 11:57 am Purchase | 2020-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | VANGUARD GROUP INC | 3,440,460 7.140% | 1,475,226 (+75.07%) | Filing History |
| 2021-02-08 10:35 am Purchase | 2021-02-05 | 13G | Turning Point Therapeutics, Inc. TPTX | FMR CORP | 6,215,362 12.902% | 1,374,716 (+28.40%) | Filing History |
| 2021-02-01 08:23 am Purchase | 2020-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | BlackRock Inc. BLK | 3,157,387 6.600% | 1,026,556 (+48.18%) | Filing History |
| 2020-11-06 5:26 pm Purchase | 2020-10-29 | 13D | Turning Point Therapeutics, Inc. TPTX | GLAXOSMITHKLINE PLC | 2,273,618 4.900% | 4,958 (+0.22%) | Filing History |
| 2020-05-26 5:06 pm Purchase | 2020-05-21 | 13D | Turning Point Therapeutics, Inc. TPTX | GLAXOSMITHKLINE PLC | 2,268,660 5.500% | 276,110 (+13.86%) | Filing History |
| 2020-05-22 4:54 pm Unchanged | 2020-05-21 | 13D | Turning Point Therapeutics, Inc. TPTX | ORBIMED ADVISORS LLC | 2,027,550 4.900% | 0 (Unchanged) | Filing History |